ReviewPharmaceuticals (Basel, Switzerland)2022
Antiosteoporosis Effects, Pharmacokinetics, and Drug Delivery Systems of Icaritin: Advances and Prospects.
Review in Pharmaceuticals (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.
- Mechanisms and traditional Chinese medicine therapeutics for primary osteoporosis: an integrated perspective.Frontiers in endocrinology · 2025Pooled it
- Icaritin improves pregnancy outcomes in endometriosis by inhibiting ovarian granulosa cell senescence.Molecular biology reports · 2026Article
- Targeting the osteoporotic bone microenvironment: Mechanistic insight and therapeutic biomaterials for accelerating bone regeneration.Bioactive materials · 2026Review
- The role of bioactive molecules in enhancing bone healing in oral and maxillofacial surgery: a review of current approaches and future directions.Oral and maxillofacial surgery · 2026Review
- Review
- Therapeutic potential of natural products from Traditional Chinese Medicine in the treatment of osteoporosis.Frontiers in pharmacology · 2026Review
- Osteoimmuno-brain axis: a bridge connecting osteoporosis and cognitive decline and its clinical significance in dementia and Alzheimer's disease.Frontiers in immunology · 2026Review
- Icariin-loaded GelMa hydrogel encapsulated potassium sodium niobate biomimetic piezoelectric scaffold regulates macrophage polarization to accelerate bone defect repair.Materials today. Bio · 2025Article
- Exploring Cannabidiol's Role in Regenerative Medicine: Focus on Neural and Skeletal Tissues.Biomedicines · 2025Review
- Review
- Research Progress on Icariin Promoting Bone Injury Repair and Regeneration.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Involvement of icaritin in the regulation of osteocyte exosomal microRNAs.Journal of orthopaedic surgery and research · 2025Article
- Potential efficacy and mechanisms of icariin for the animal model of osteonecrosis of the femoral head.Frontiers in pharmacology · 2025Article
- Two new species ofMycoKeys · 2025Article
- Progress in the application of epimedium and its major bioactive components in the treatment of orthopedic diseases.Frontiers in pharmacology · 2025Review
- Icaritin inhibits osteoclast differentiation and reduces bone loss by targeting ESR1 to inhibit miR503/RANK pathway.Frontiers in pharmacology · 2025Article
- Integrating bioprinting, cell therapies and drug delivery towards in vivo regeneration of cartilage, bone and osteochondral tissue.Drug delivery and translational research · 2024Review
- Exploring the therapeutic potential of isoorientin in the treatment of osteoporosis: a study using network pharmacology and experimental validation.Molecular medicine (Cambridge, Mass.) · 2024Article
- N-Ethyl-N-Nitrosourea Induced Leukaemia in a Mouse Model: Protective Effect of Icaritin via Inhibition of IL-6/JAK2/STAT3 Pathway Causes Apoptosis.Journal of inflammation research · 2024Article
- Comprehensive review of the traditional uses and the potential benefits of epimedium folium.Frontiers in pharmacology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Osteoporosis is a systemic skeletal disorder affecting over 200 million people worldwide and contributes dramatically to global healthcare costs. Available anti-osteoporotic drug treatments including hormone replacement therapy, anabolic agents, and bisphosphonates often cause adverse events which limit their long-term use. Therefore, the application of natural products has been proposed as an alternative therapy strategy. Icaritin (ICT) is not only an enzyme-hydrolyzed product of icariin but also an intestinal metabolite of eight major flavonoids of the traditional Chinese medicinal plant
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.